Pharvaris (NASDAQ:PHVS) Rating Increased to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Pharvaris (NASDAQ:PHVS) from a strong sell rating to a sell rating in a report released on Saturday.

Several other research analysts also recently commented on PHVS. HC Wainwright reissued a “buy” rating and issued a $60.00 price target on shares of Pharvaris in a report on Tuesday, March 3rd. UBS Group set a $74.00 price target on shares of Pharvaris in a report on Wednesday. Citigroup reissued a “buy” rating on shares of Pharvaris in a report on Wednesday, April 15th. Wolfe Research initiated coverage on shares of Pharvaris in a report on Thursday, April 9th. They issued an “outperform” rating and a $42.00 price target for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a report on Tuesday, April 21st. Ten analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $49.18.

Pharvaris Price Performance

Shares of NASDAQ:PHVS opened at $30.40 on Friday. The firm has a fifty day moving average price of $28.14 and a two-hundred day moving average price of $26.56. Pharvaris has a one year low of $15.46 and a one year high of $33.33. The company has a market cap of $1.99 billion, a price-to-earnings ratio of -9.56 and a beta of -2.34.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.82) by $0.12. Equities research analysts expect that Pharvaris will post -3.35 EPS for the current fiscal year.

Insider Activity

In related news, insider Peng Lu sold 15,000 shares of Pharvaris stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $30.24, for a total value of $453,600.00. Following the transaction, the insider owned 66,083 shares in the company, valued at $1,998,349.92. This trade represents a 18.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Johannes Gerardus Chri Schikan sold 29,070 shares of Pharvaris stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $30.32, for a total transaction of $881,402.40. Following the completion of the transaction, the director owned 355,167 shares in the company, valued at approximately $10,768,663.44. The trade was a 7.57% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 150,659 shares of company stock worth $4,489,587. 11.84% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Pharvaris

A number of large investors have recently added to or reduced their stakes in the business. California State Teachers Retirement System raised its position in Pharvaris by 2.2% in the 4th quarter. California State Teachers Retirement System now owns 23,982 shares of the company’s stock worth $666,000 after purchasing an additional 520 shares during the period. JPMorgan Chase & Co. raised its position in Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after purchasing an additional 783 shares during the period. GF Fund Management CO. LTD. purchased a new position in Pharvaris in the 4th quarter worth $35,000. Public Employees Retirement System of Ohio raised its position in Pharvaris by 20.7% in the 4th quarter. Public Employees Retirement System of Ohio now owns 7,569 shares of the company’s stock worth $210,000 after purchasing an additional 1,300 shares during the period. Finally, Legal & General Group Plc raised its position in Pharvaris by 17.2% in the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after purchasing an additional 1,695 shares during the period.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.